Compare CIVI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVI | CELC |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2011 | 2017 |
| Metric | CIVI | CELC |
|---|---|---|
| Price | $27.19 | $102.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $40.80 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.3M | 858.0K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.86 | N/A |
| Revenue | ★ $4,711,808,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.79 | $7.58 |
| 52 Week High | $55.35 | $112.64 |
| Indicator | CIVI | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 64.34 |
| Support Level | $26.95 | $97.27 |
| Resistance Level | $28.56 | $112.64 |
| Average True Range (ATR) | 1.04 | 5.11 |
| MACD | -0.28 | -1.32 |
| Stochastic Oscillator | 14.83 | 48.78 |
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.